Coherus Oncology to Release Q1 2026 Financial Results on May 11
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy CHRS?
Source: Newsfilter
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CHRS
Wall Street analysts forecast CHRS stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.750
Low
4.00
Averages
5.50
High
7.00
Current: 1.750
Low
4.00
Averages
5.50
High
7.00
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Coherus Oncology to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus Oncology Q4 2025 Earnings Call Highlights
- Successful Strategic Transformation: Coherus Oncology has completed its strategic pivot to focus on innovative oncology, acquiring Surface Oncology and reducing debt from $480 million to $38.8 million, a reduction of over 90%, significantly improving its financial position.
- LOQTORZI Sales Growth: LOQTORZI's net revenue reached $40.8 million in 2025, up 113% from $19.1 million in 2024, with expectations to achieve $175 million in annual revenue by 2028, capturing a 70% market share of a $250 million addressable market.
- Significant Cost Control: The company reported SG&A expenses of $23.6 million in Q4, down from $29.6 million in the same quarter last year, demonstrating substantial operational efficiency improvements, while R&D expenses increased to $31 million.
- Optimistic Future Outlook: Management anticipates a quarter-over-quarter demand growth of 10% to 15% for LOQTORZI and plans to provide revenue guidance for 2026 in the next earnings call, reflecting confidence in future market potential.
See More
Coherus BioSciences Reports Q4 Earnings Miss
- Earnings Miss: Coherus BioSciences reported a Q4 non-GAAP EPS of -$0.34, missing expectations by $0.03, indicating challenges in profitability that could undermine investor confidence.
- Revenue Growth Lag: Despite a 64.9% year-over-year revenue increase to $12.7M, the figure fell short of market expectations by $1.39M, reflecting competitive pressures that may impact future cash flows.
- Rating Downgrade: Analysts downgraded Coherus to 'Hold' due to potential advancements of the anti-CCR8 CHS-114, which may lower investor expectations for future growth and affect stock performance.
- Funding Initiative: Coherus Oncology announced a stock offering priced to raise $50.1M to support future R&D projects, a move that may dilute existing shareholders but provides essential funding for the company's growth initiatives.
See More
Coherus BioSciences to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Coherus BioSciences is set to release its Q4 2023 earnings on March 9 after market close, with a consensus EPS estimate of -$0.31, reflecting a 10.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $14.09 million, representing a staggering 74% year-over-year decrease, which highlights major challenges in market competition and product sales that could impact investor confidence moving forward.
- Historical Performance Review: Over the past two years, Coherus has only beaten EPS estimates 13% of the time and revenue estimates 63% of the time, indicating considerable volatility in its performance, prompting investors to exercise caution in evaluating future outcomes.
- Stock Offering Update: Coherus Oncology recently announced a proposed public offering of common stock to raise $50.1 million, a move that may dilute existing shareholders while underscoring the company's urgent need for capital.
See More
Coherus Oncology to Release 2025 Financial Results on March 9, 2026
- Earnings Release Schedule: Coherus Oncology will announce its full-year and fourth-quarter 2025 financial results after market close on March 9, 2026, which may influence investor confidence.
- Conference Call Details: The management team will host a conference call at 4:30 p.m. Eastern Time on March 9 to discuss financial results and provide a business update, enhancing transparency and investor communication.
- Webcast Replay Availability: A replay of the webcast will be accessible on the company's investor website following the conclusion of the call, ensuring that investors who cannot attend can still access critical information.
- Company Strategy Overview: Coherus Oncology focuses on growing sales of its PD-1 inhibitor LOQTORZI® and advancing the development of new indications, aiming to enhance market competitiveness through innovative anti-tumor therapies.
See More
Coherus Oncology to Release Q1 2026 Financial Results on May 11
- Earnings Release Schedule: Coherus Oncology will release its Q1 2026 financial results after market close on May 11, which is expected to impact the company's future market performance.
- Management Conference Call: The management team will host a conference call at 5:00 p.m. ET on May 11 to discuss financial results and provide a business update, enhancing investor understanding of the company's strategy.
- Webcast Replay Availability: Investors can access a replay of the webcast on the company's website after the live call, ensuring transparency and compliance with regulatory requirements.
- Innovative Drug Pipeline: Coherus Oncology has a range of innovative oncology drugs, including the approved PD-1 inhibitor LOQTORZI®, and is advancing clinical candidates targeting various cancers, demonstrating the company's strategic positioning in cancer treatment.
See More
Coherus Oncology Reports Strong 2025 Financial Results
- Significant Revenue Growth: Coherus Oncology reported a net revenue of $40.8 million for 2025, a remarkable 113% increase from $19.1 million in 2024, indicating strong market acceptance of its next-gen PD-1 inhibitor, LOQTORZI, and suggesting enhanced future sales potential.
- Substantial Debt Reduction: The company successfully reduced its debt from $480 million to $38.8 million, a decrease of over 90%, significantly improving its financial position and providing greater funding flexibility for future R&D and market expansion.
- Increased R&D Spending: Despite overall cost control, Coherus raised its R&D expenses from $20.8 million to $31 million in Q4 2025, reflecting the company's commitment to new product development aimed at maintaining competitive advantage through innovation.
- Strong Cash Position: At the end of 2025, the company reported cash, cash equivalents, and investments totaling $172.1 million, ensuring financial stability for future operations and supporting potential strategic investments.
See More
Coherus Oncology Q4 2025 Earnings Call Highlights
- Successful Strategic Transformation: Coherus Oncology has completed its strategic pivot to focus on innovative oncology, acquiring Surface Oncology and reducing debt from $480 million to $38.8 million, a reduction of over 90%, significantly improving its financial position.
- LOQTORZI Sales Growth: LOQTORZI's net revenue reached $40.8 million in 2025, up 113% from $19.1 million in 2024, with expectations to achieve $175 million in annual revenue by 2028, capturing a 70% market share of a $250 million addressable market.
- Significant Cost Control: The company reported SG&A expenses of $23.6 million in Q4, down from $29.6 million in the same quarter last year, demonstrating substantial operational efficiency improvements, while R&D expenses increased to $31 million.
- Optimistic Future Outlook: Management anticipates a quarter-over-quarter demand growth of 10% to 15% for LOQTORZI and plans to provide revenue guidance for 2026 in the next earnings call, reflecting confidence in future market potential.
See More
Coherus BioSciences Reports Q4 Earnings Miss
- Earnings Miss: Coherus BioSciences reported a Q4 non-GAAP EPS of -$0.34, missing expectations by $0.03, indicating challenges in profitability that could undermine investor confidence.
- Revenue Growth Lag: Despite a 64.9% year-over-year revenue increase to $12.7M, the figure fell short of market expectations by $1.39M, reflecting competitive pressures that may impact future cash flows.
- Rating Downgrade: Analysts downgraded Coherus to 'Hold' due to potential advancements of the anti-CCR8 CHS-114, which may lower investor expectations for future growth and affect stock performance.
- Funding Initiative: Coherus Oncology announced a stock offering priced to raise $50.1M to support future R&D projects, a move that may dilute existing shareholders but provides essential funding for the company's growth initiatives.
See More
Coherus BioSciences to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Coherus BioSciences is set to release its Q4 2023 earnings on March 9 after market close, with a consensus EPS estimate of -$0.31, reflecting a 10.7% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $14.09 million, representing a staggering 74% year-over-year decrease, which highlights major challenges in market competition and product sales that could impact investor confidence moving forward.
- Historical Performance Review: Over the past two years, Coherus has only beaten EPS estimates 13% of the time and revenue estimates 63% of the time, indicating considerable volatility in its performance, prompting investors to exercise caution in evaluating future outcomes.
- Stock Offering Update: Coherus Oncology recently announced a proposed public offering of common stock to raise $50.1 million, a move that may dilute existing shareholders while underscoring the company's urgent need for capital.
See More
Coherus Oncology to Release 2025 Financial Results on March 9, 2026
- Earnings Release Schedule: Coherus Oncology will announce its full-year and fourth-quarter 2025 financial results after market close on March 9, 2026, which may influence investor confidence.
- Conference Call Details: The management team will host a conference call at 4:30 p.m. Eastern Time on March 9 to discuss financial results and provide a business update, enhancing transparency and investor communication.
- Webcast Replay Availability: A replay of the webcast will be accessible on the company's investor website following the conclusion of the call, ensuring that investors who cannot attend can still access critical information.
- Company Strategy Overview: Coherus Oncology focuses on growing sales of its PD-1 inhibitor LOQTORZI® and advancing the development of new indications, aiming to enhance market competitiveness through innovative anti-tumor therapies.
See More
